GSK completes Novartis vaccines purchase; Galena announces positive PhIIb cancer vax results;

> GlaxoSmithKline ($GSK) completed its acquisition of Novartis' ($NVS) vaccine business. Story

> Galena Biopharma announced positive Phase IIa results of its GALE-301 immunotherapy in preventing the recurrence of ovarian and endometrial cancers. Galena also identified an optimal dose. Statement

> Aduro ($ADRO), through a $32 million purchase of Dutch biotech BioNovion, added an in-house preclinical pipeline of antibodies and checkpoint inhibitors. Report

> Researchers at the University of Rochester Medical Center received $3.1 million from the NIH to look for new ways to develop an HIV vaccine. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.